Higher Risk Breast Cancer Patients for Lymphedema
Breast cancer patients who undergo axillary lymph node dissection (ALND), receive radiation therapy to the supraclavicular or axillary lymph nodes, are obese, or have five or more lymph nodes removed are at highest risk for developing lymphedema. 1
Treatment-Related Risk Factors
The most significant risk factors are treatment-related:
Surgical Factors
- Axillary lymph node dissection (ALND) carries substantially higher risk than sentinel lymph node biopsy (SLNB) 1, 2
- Removal of ≥5 lymph nodes significantly increases risk 1, 3
- Mastectomy increases risk compared to lumpectomy 3
- Lymphedema incidence is much lower with SLNB than with full ALND 1
Radiation Therapy
- Radiation to supraclavicular lymph nodes markedly increases risk 1
- Axillary radiation causes or exacerbates lymphedema 1
- Regional lymph node radiation (RLNR) is associated with late-onset lymphedema (>12 months post-treatment) 2
- Radiotherapy increases risk with hazard ratio of 2.19 4
Chemotherapy
- Adjuvant chemotherapy increases odds of lymphedema (aOR = 2.14) 5
- Neoadjuvant chemotherapy increases odds even more (aOR = 3.05) 5
- Chemotherapy infusion in the affected limb increases risk (HR = 1.45) 4
Patient-Specific Risk Factors
Body Composition
- Obesity is a major modifiable risk factor 1, 4
- Breast volume ≥1500 cm³ increases odds (aOR = 2.34) 5
- High preoperative body mass index significantly increases risk 2
Demographic Factors
- Black patients have higher odds of developing breast lymphedema (aOR = 1.78) 5
- Younger Black women have the highest risk starting approximately 10 months after diagnosis 3
- Older non-Black women have the lowest risk 3
Tumor Characteristics
- Positive lymph node status increases hazard 1.5- to 3.5-fold 3
- Tumor size >5 cm increases risk 3
- Estrogen receptor-negative breast cancer increases risk 3
- Advanced disease staging (HR = 1.41) 4
Complication-Related Risk Factors
- Postoperative cellulitis dramatically increases odds (aOR = 3.94) 5
- Seroma formation after surgery increases risk (HR = 1.46) 4
- Development of arm lymphedema increases odds of breast lymphedema (aOR = 2.94) 5
Combined Risk Stratification
Highest risk patients (5-year lymphedema rate 31.2%): Those receiving ALND with regional lymph node radiation 2
High risk patients (5-year rate 24.6%): Those receiving ALND without radiation 2
Moderate risk patients (5-year rate 12.2%): Those receiving SLNB with regional lymph node radiation 2
Timing Considerations
The risk profile varies by treatment:
- ALND without radiation: Peak risk 6-12 months post-treatment 2
- ALND with radiation: Peak risk 18-24 months post-treatment 2
- SLNB with radiation: Peak risk 36-48 months post-treatment 2
- Overall peak risk: 12-30 months postoperatively 2
Clinical Implications
All breast cancer survivors who undergo breast surgery and/or radiation are at some risk for lymphedema 1. The incidence varies widely, with estimates that over 40% of survivors will experience lymphedema to some degree 1. Cumulative incidence reaches 13.5% at 2 years, 30.2% at 5 years, and 41.1% at 10 years in high-risk populations 4.